Effects of survivin antagonists on growth of established tumors and B7-1 immunogene therapy

Journal of the National Cancer Institute

Volumn 93, Issue 20, 2001, Pages 1541-1552

  Kanwar, J R ^a   Shen, W P ^a   Kanwar, R K ^a   Berg, R W ^a   Krissansen, G W ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

[No Author keywords available]

Indexed keywords

B7 ANTIGEN; INHIBITOR OF APOPTOSIS PROTEIN; SURVIVIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER IMMUNOTHERAPY; CELL ISOLATION; CONTROLLED STUDY; CYTOTOXIC T LYMPHOCYTE; FEMALE; FLOW CYTOMETRY; GENE THERAPY; IMMUNOGENETICS; IMMUNOHISTOCHEMISTRY; LYMPHOCYTE ACTIVATION; LYMPHOCYTE SUBPOPULATION; MEASUREMENT; MOUSE; NONHUMAN; NUCLEOTIDE SEQUENCE; PLASMID; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; T LYMPHOCYTE; THYMUS LYMPHOMA; TISSUE SECTION; TUMOR CELL; TUMOR GROWTH; WESTERN BLOTTING;

EID: 0035904376     PISSN: 00278874     EISSN: None     Source Type: Journal    
DOI: 10.1093/jnci/93.20.1541     Document Type: Article

References (55)

1. Dysregulation of apoptosis in cancer
2. BIRinging chromosomes through cell division-and survivin' the experience
3. Escaping cell death: Survival proteins in cancer
4. The inhibitors of apoptosis (IAPs) and their emerging role in cancer
5. A conserved family of cellular genes related to the baculovirus iap gene and encoding apoptosis inhibitors
6. Bcl-2 and the regulation of programmed cell death
7. Apoptosis by death factor
8. Molecular thanatopsis: A discourse on the BCL2 family and cell death
9. Caspase-3 and inhibitor of apoptosis protein(s) interaction in Saccharomyces cerevisiae and mammalian cells
10. A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma
11. Structure of the human anti-apoptotic protein survivin reveals a dimeric arrangement
12. Crystal structure of human survivin reveals a bow tie-shaped dimer with two unusual alpha-helical extensions
13. Crystal structure and mutagenic analysis of the inhibitor-of-apoptosis protein survivin
14. Expression of survivin and Bcl-2 in the normal human endometrium
15. Communication: Expression of the novel inhibitor of apoptosis survivin in normal and neoplastic skin
16. Prognostic significance of survivin expression in diffuse large B-cell lymphomas
17. Expression of the antiapoptosis gene, survivin, predicts death from recurrent colorectal carcinoma
18. High expression of Survivin, mapped to 17q25, is significantly associated with poor prognostic factors and promotes cell survival in human neuroblastoma
19. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas
20. A novel anti-apoptosis gene: Re-expression of survivin messenger RNA as a prognosis marker in non-small-cell lung cancers
21. Survivin' cell-separation anxiety
22. Control of apoptosis and mitotic spindle checkpoint by survivin
23. Survivin initiates cell cycle entry by the competitive interaction with Cdk4/p16(INK4a) and Cdk2/cyclin E complex activation
24. Survivin promotes cell proliferation in human hepatocellular carcinoma
25. Survivin initiates procaspase 3/p21 complex formation as a result of interaction with Cdk4 to resist Fas-mediated cell death
26. An anti-apoptotic protein human survivin is a direct inhibitor of caspase-3 and -7
27. Smac, a mitochondrial protein that promotes cytochrome c-dependent caspase activation by eliminating IAP inhibition
28. BCL-2 antisense therapy in patients with non-Hodgkin lymphoma
29. Chemosensitization and delayed androgen-independent recurrence of prostate cancer with the use of antisense Bcl-2 oligodeoxynucleotides
30. In vivo electrophoretic transfer of bcl-2 antisense oligonucleotide inhibits the development of hepatocellular carcinoma in rats
31. Pleiotropic cell-division defects and apoptosis induced by interference with survivin function
32. Down-regulation of survivin by antisense oligonucleotides increases apoptosis, inhibits cytokinesis and anchorage-independent growth
33. Expression and targeting of the apoptosis inhibitor, survivin, in human melanoma
34. A novel antisense oligonucleotide targeting survivin expression induces apoptosis and sensitizes lung cancer cells to chemotherapy
35. Control of apoptosis during angiogenesis by survivin expression in endothelial cells
36. Marked induction of the IAP family antiapoptotic proteins survivin and XIAP by VEGF in vascular endothelial cells
37. Angiopoietin-1 inhibits endothelial cell apoptosis via the Akt/survivin pathway
38. Taking lessons from dendritic cells: Multiple xenogeneic ligands for leukocyte integrins have the potential to stimulate anti-tumor immunity
39. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci
40. Gene transfer of antisense hypoxia inducible factor-1α enhances the therapeutic efficacy of cancer immunotherapy
41. Inhibition of cell growth and induction of apoptotic cell death by the human tumor-associated antigen RCAS1
42. Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction
43. The cancer antiapoptosis mouse survivin gene: Characterization of locus and transcriptional requirements of basal and cell cycle-dependent expression
44. In situ detection of apoptosis in dental and periodontal tissues of the adult mouse using annexin-V-biotin
45. A method for isolating large numbers of viable disaggregated cells from various human tissues for cell culture establishment
46. Cloning and functional characteristics of murine large granular-lymphocyte-1: A member of the Ly-49 gene family (Ly-49G2)
47. Determination of total protein
48. Costimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4
49. Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance
50. Impediments to successful immunotherapy
51. Reversal of tumor-induced immunosuppression: A new approach to cancer therapy
52. The great escape: Is immune evasion required for tumor progression?
53. Angiogenesis inhibitors overcome tumor induced endothelial cell anergy
54. Fas counter-attack-the best form of tumor defense?
55. Human naive B cells cultured with EL-4 T cells mimic a germinal center-related B cell stage before generating plasma cells Concordant changes in Bcl-2 protein and messenger RNA levels